These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 29712896)

  • 1. Daratumumab, lenalidomide, and dexamethasone in East Asian patients with relapsed or refractory multiple myeloma: subgroup analyses of the phase 3 POLLUX study.
    Suzuki K; Dimopoulos MA; Takezako N; Okamoto S; Shinagawa A; Matsumoto M; Kosugi H; Yoon SS; Huang SY; Qin X; Qi M; Iida S
    Blood Cancer J; 2018 May; 8(4):41. PubMed ID: 29712896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Daratumumab plus lenalidomide and dexamethasone
    Dimopoulos MA; San-Miguel J; Belch A; White D; Benboubker L; Cook G; Leiba M; Morton J; Ho PJ; Kim K; Takezako N; Moreau P; Kaufman JL; Sutherland HJ; Lalancette M; Magen H; Iida S; Kim JS; Prince HM; Cochrane T; Oriol A; Bahlis NJ; Chari A; O'Rourke L; Wu K; Schecter JM; Casneuf T; Chiu C; Soong D; Sasser AK; Khokhar NZ; Avet-Loiseau H; Usmani SZ
    Haematologica; 2018 Dec; 103(12):2088-2096. PubMed ID: 30237262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study.
    Bahlis NJ; Dimopoulos MA; White DJ; Benboubker L; Cook G; Leiba M; Ho PJ; Kim K; Takezako N; Moreau P; Kaufman JL; Krevvata M; Chiu C; Qin X; Okonkwo L; Trivedi S; Ukropec J; Qi M; San-Miguel J
    Leukemia; 2020 Jul; 34(7):1875-1884. PubMed ID: 32001798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of Daratumumab-based Triplet Therapies in Patients With Relapsed or Refractory Multiple Myeloma.
    Zhang TT; Wang S; Wan N; Zhang L; Zhang Z; Jiang J
    Clin Ther; 2018 Jul; 40(7):1122-1139. PubMed ID: 30006069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX.
    Kaufman JL; Dimopoulos MA; White D; Benboubker L; Cook G; Leiba M; Morton J; Joy Ho P; Kim K; Takezako N; Moreau P; Sutherland HJ; Magen H; Iida S; Kim JS; Miles Prince H; Cochrane T; Oriol A; Bahlis NJ; Chari A; O'Rourke L; Trivedi S; Casneuf T; Krevvata M; Ukropec J; Kobos R; Avet-Loiseau H; Usmani SZ; San-Miguel J
    Blood Cancer J; 2020 Nov; 10(11):111. PubMed ID: 33149130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Efficacy of Treatments for Previously Treated Multiple Myeloma: A Systematic Literature Review and Network Meta-analysis.
    Maiese EM; Ainsworth C; Le Moine JG; Ahdesmäki O; Bell J; Hawe E
    Clin Ther; 2018 Mar; 40(3):480-494.e23. PubMed ID: 29500140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health-related quality of life in patients with relapsed or refractory multiple myeloma: treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trial.
    Plesner T; Dimopoulos MA; Oriol A; San-Miguel J; Bahlis NJ; Rabin N; Suzuki K; Yoon SS; Ben-Yehuda D; Cook G; Goldschmidt H; Grosicki S; Qin X; Fastenau J; Garvin W; Carson R; Renaud T; Gries KS
    Br J Haematol; 2021 Jul; 194(1):132-139. PubMed ID: 33822368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR.
    Avet-Loiseau H; San-Miguel J; Casneuf T; Iida S; Lonial S; Usmani SZ; Spencer A; Moreau P; Plesner T; Weisel K; Ukropec J; Chiu C; Trivedi S; Amin H; Krevvata M; Ramaswami P; Qin X; Qi M; Sun S; Qi M; Kobos R; Bahlis NJ
    J Clin Oncol; 2021 Apr; 39(10):1139-1149. PubMed ID: 33513030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
    Dimopoulos MA; Oriol A; Nahi H; San-Miguel J; Bahlis NJ; Usmani SZ; Rabin N; Orlowski RZ; Komarnicki M; Suzuki K; Plesner T; Yoon SS; Ben Yehuda D; Richardson PG; Goldschmidt H; Reece D; Lisby S; Khokhar NZ; O'Rourke L; Chiu C; Qin X; Guckert M; Ahmadi T; Moreau P;
    N Engl J Med; 2016 Oct; 375(14):1319-1331. PubMed ID: 27705267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of adding daratumumab or bortezomib to lenalidomide plus dexamethasone for newly diagnosed multiple myeloma.
    Narsipur N; Bulla S; Yoo C; Do B; Tran K; Gu D; Zhong L; Wilson L
    J Manag Care Spec Pharm; 2021 Dec; 27(12):1691-1702. PubMed ID: 34818089
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficacy of daratumumab-based therapies in patients with relapsed, refractory multiple myeloma treated outside of clinical trials.
    Lakshman A; Abeykoon JP; Kumar SK; Rajkumar SV; Dingli D; Buadi FK; Gonsalves WI; Leung N; Dispenzieri A; Kourelis TV; Go RS; Lacy MQ; Hobbs MA; Lin Y; Warsame R; Lust J; Fonder AL; Hwa YL; Hayman SR; Russell SJ; Kyle RA; Gertz MA; Kapoor P
    Am J Hematol; 2017 Nov; 92(11):1146-1155. PubMed ID: 28799231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial.
    Dimopoulos MA; Lonial S; Betts KA; Chen C; Zichlin ML; Brun A; Signorovitch JE; Makenbaeva D; Mekan S; Sy O; Weisel K; Richardson PG
    Cancer; 2018 Oct; 124(20):4032-4043. PubMed ID: 30204239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial.
    Dimopoulos MA; Oriol A; Nahi H; San-Miguel J; Bahlis NJ; Usmani SZ; Rabin N; Orlowski RZ; Suzuki K; Plesner T; Yoon SS; Ben Yehuda D; Richardson PG; Goldschmidt H; Reece D; Ahmadi T; Qin X; Garvin Mayo W; Gai X; Carey J; Carson R; Moreau P
    J Clin Oncol; 2023 Mar; 41(8):1590-1599. PubMed ID: 36599114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative effectiveness of lenalidomide/dexamethasone-based triplet regimens for treatment of relapsed and/or refractory multiple myeloma in the United States: An analysis of real-world electronic health records data.
    Ailawadhi S; Cheng M; Cherepanov D; DerSarkissian M; Stull DM; Hilts A; Chun J; Duh MS; Sanchez L
    Curr Probl Cancer; 2024 Jun; 50():101078. PubMed ID: 38547609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carfilzomib, dexamethasone, and daratumumab in Asian patients with relapsed or refractory multiple myeloma: post hoc subgroup analysis of the phase 3 CANDOR trial.
    Suzuki K; Min CK; Kim K; Lee JJ; Shibayama H; Ko PS; Huang SY; Li SS; Ding B; Khurana M; Iida S
    Int J Hematol; 2021 Dec; 114(6):653-663. PubMed ID: 34410635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Daratumumab for patients with myeloma with early or late relapse after initial therapy: subgroup analysis of CASTOR and POLLUX.
    Spencer A; Moreau P; Mateos MV; Goldschmidt H; Suzuki K; Levin MD; Sonneveld P; Orlowski RZ; Yoon SS; Usmani SZ; Weisel K; Reece D; Ahmadi T; Pei H; Mayo WG; Gai X; Carey J; Bartlett JB; Carson R; Dimopoulos MA
    Blood Adv; 2024 Jan; 8(2):388-398. PubMed ID: 38048391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma.
    Chari A; Martinez-Lopez J; Mateos MV; Bladé J; Benboubker L; Oriol A; Arnulf B; Rodriguez-Otero P; Pineiro L; Jakubowiak A; de Boer C; Wang J; Clemens PL; Ukropec J; Schecter J; Lonial S; Moreau P
    Blood; 2019 Aug; 134(5):421-431. PubMed ID: 31113777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone
    Mateos MV; Masszi T; Grzasko N; Hansson M; Sandhu I; Pour L; Viterbo L; Jackson SR; Stoppa AM; Gimsing P; Hamadani M; Borsaru G; Berg D; Lin J; Di Bacco A; van de Velde H; Richardson PG; Moreau P
    Haematologica; 2017 Oct; 102(10):1767-1775. PubMed ID: 28751562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Daratumumab plus bortezomib and dexamethasone
    Spencer A; Lentzsch S; Weisel K; Avet-Loiseau H; Mark TM; Spicka I; Masszi T; Lauri B; Levin MD; Bosi A; Hungria V; Cavo M; Lee JJ; Nooka AK; Quach H; Lee C; Barreto W; Corradini P; Min CK; Scott EC; Chanan-Khan AA; Horvath N; Capra M; Beksac M; Ovilla R; Jo JC; Shin HJ; Sonneveld P; Soong D; Casneuf T; Chiu C; Amin H; Qi M; Thiyagarajah P; Sasser AK; Schecter JM; Mateos MV
    Haematologica; 2018 Dec; 103(12):2079-2087. PubMed ID: 30237264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.
    Facon T; Kumar S; Plesner T; Orlowski RZ; Moreau P; Bahlis N; Basu S; Nahi H; Hulin C; Quach H; Goldschmidt H; O'Dwyer M; Perrot A; Venner CP; Weisel K; Mace JR; Raje N; Attal M; Tiab M; Macro M; Frenzel L; Leleu X; Ahmadi T; Chiu C; Wang J; Van Rampelbergh R; Uhlar CM; Kobos R; Qi M; Usmani SZ;
    N Engl J Med; 2019 May; 380(22):2104-2115. PubMed ID: 31141632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.